These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 22747578)

  • 1. The make or buy debate: considering the limitations of domestic production in Tanzania.
    Wilson KR; Kohler JC; Ovtcharenko N
    Global Health; 2012 Jun; 8():20. PubMed ID: 22747578
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Trade-Related Aspects of Intellectual Property Rights Flexibilities and Public Health: Implementation of Compulsory Licensing Provisions into National Patent Legislation.
    McGIVERN L
    Milbank Q; 2023 Dec; 101(4):1280-1303. PubMed ID: 37646392
    [TBL] [Abstract][Full Text] [Related]  

  • 3. What strategies to boost production of affordable fixed-dose anti-retroviral drug combinations for children in the developing world?
    Dionisio D; Gass R; McDermott P; Racalbuto V; Madeo M; Braghieri G; Crowley S; Pinheiro Edos S; Graaff P; Vasan A; Eksaengsri A; Moller H; Khanna AK; Kraisintu K; Juneja S; Nicolaou S; Sengupta A; Esperti F; Messeri D
    Curr HIV Res; 2007 Mar; 5(2):155-87. PubMed ID: 17346132
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Does the political will exist to bring quality-assured and affordable drugs to low- and middle-income countries?
    Beck EJ; Mandalia S; DongmoNguimfack B; Pinheiro E; 't Hoen E; Boulet P; Stover J; Gupta A; Juneja S; Habiyambere V; Ghys P; Nunez C
    Glob Health Action; 2019; 12(1):1586317. PubMed ID: 30983547
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Affordable antiretroviral drugs for the under-served markets: how to expand equitable access against the backdrop of challenging scenarios?
    Dionisio D; Cao Y; Hongzhou L; Kraisintu K; Messeri D
    Curr HIV Res; 2006 Jan; 4(1):3-20. PubMed ID: 16454707
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Medicine procurement and the use of flexibilities in the Agreement on Trade-Related Aspects of Intellectual Property Rights, 2001-2016.
    't Hoen EF; Veraldi J; Toebes B; Hogerzeil HV
    Bull World Health Organ; 2018 Mar; 96(3):185-193. PubMed ID: 29531417
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A method for understanding generic procurement of HIV medicines by developing countries with patent protection.
    Beall RF; Attaran A
    Soc Sci Med; 2017 Jul; 185():118-126. PubMed ID: 28578209
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Soaring antiretroviral prices, TRIPS and TRIPS flexibilities: a burning issue for antiretroviral treatment scale-up in developing countries.
    Orsi F; d'almeida C
    Curr Opin HIV AIDS; 2010 May; 5(3):237-41. PubMed ID: 20539080
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A lifeline to treatment: the role of Indian generic manufacturers in supplying antiretroviral medicines to developing countries.
    Waning B; Diedrichsen E; Moon S
    J Int AIDS Soc; 2010 Sep; 13():35. PubMed ID: 20840741
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Factors influencing global antiretroviral procurement prices.
    Wirtz VJ; Forsythe S; Valencia-Mendoza A; Bautista-Arredondo S
    BMC Public Health; 2009 Nov; 9 Suppl 1(Suppl 1):S6. PubMed ID: 19922690
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of intellectual property rights on access to medicines in the WHO African region: 25 years after the TRIPS agreement.
    Motari M; Nikiema JB; Kasilo OMJ; Kniazkov S; Loua A; Sougou A; Tumusiime P
    BMC Public Health; 2021 Mar; 21(1):490. PubMed ID: 33706726
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Has the implementation of the TRIPS Agreement in Latin America and the Caribbean produced intellectual property legislation that favours public health?
    Oliveira MA; Bermudez JA; Chaves GC; Velásquez G
    Bull World Health Organ; 2004 Nov; 82(11):815-21. PubMed ID: 15640916
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patent challenges in the procurement and supply of generic new essential medicines and lessons from HIV in the southern African development community (SADC) region.
    't Hoen EFM; Kujinga T; Boulet P
    J Pharm Policy Pract; 2018; 11():31. PubMed ID: 30524732
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antiretrovirals for low income countries: an analysis of the commercial viability of a highly competitive market.
    Nakakeeto ON; Elliott BV
    Global Health; 2013 Feb; 9():6. PubMed ID: 23410145
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Trans Pacific Partnership Agreement and access to HIV treatment in Vietnam.
    Moir HVJ; Tenni B; Gleeson D; Lopert R
    Glob Public Health; 2018 Apr; 13(4):400-413. PubMed ID: 27841097
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Driving a decade of change: HIV/AIDS, patents and access to medicines for all.
    Hoen E'; Berger J; Calmy A; Moon S
    J Int AIDS Soc; 2011 Mar; 14():15. PubMed ID: 21439089
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Brazilian experiment: HIV drugs for all.
    Flaer PJ; Younis MZ
    J Health Care Finance; 2009; 36(2):90-6. PubMed ID: 20499725
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Examining the production costs of antiretroviral drugs.
    Pinheiro E; Vasan A; Kim JY; Lee E; Guimier JM; Perriens J
    AIDS; 2006 Aug; 20(13):1745-52. PubMed ID: 16931939
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aid conditionalities, international Good Manufacturing Practice standards and local production rights: a case study of local production in Nepal.
    Brhlikova P; Harper I; Subedi M; Bhattarai S; Rawal N; Pollock AM
    Global Health; 2015 Jun; 11():25. PubMed ID: 26072308
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Trade, TRIPS, and pharmaceuticals.
    Smith RD; Correa C; Oh C
    Lancet; 2009 Feb; 373(9664):684-91. PubMed ID: 19167054
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.